Preference for oral anticoagulation therapy for patients with atrial fibrillation in Europe in different clinical situations: results of the European Heart Rhythm Association Survey

Management of acute coronary syndrome in patients with non-valvular atrial fibrillation: results of the European Heart Rhythm Association Survey

(2014) T. S. Potpara et al.   EUROPACE

Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation

(2014) Riccardo Cappato et al.   EUROPEAN HEART JOURNAL

2014 ESC/EACTS Guidelines on myocardial revascularization

(2014)   EUROPEAN HEART JOURNAL

Novel oral anticoagulants for stroke prevention in atrial fibrillation: results of the European Heart Rhythm Association survey

(2013) G. Y. H. Lip et al.   EUROPACE

European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation

(2013) Hein Heidbuchel et al.   EUROPACE

Outcomes After Cardioversion and Atrial Fibrillation Ablation in Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial

(2013) Jonathan P. Piccini et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Efficacy and Safety of Apixaban in Patients After Cardioversion for Atrial Fibrillation

(2013) Greg Flaker et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial

(2013) Willem JM Dewilde et al.   LANCET

Warfarin or novel oral anticoagulants for atrial fibrillation?

(2013) Torben Bjerregaard Larsen et al.   LANCET

2012 focused update of the ESC Guidelines for the management of atrial fibrillation

(2012) et al.   EUROPACE

Dabigatran Versus Warfarin in Patients With Atrial Fibrillation

(2011) Rangadham Nagarakanti et al.   CIRCULATION